Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients

Nitta, Kosaku; Akiba, Takashi; Uchida, Keiko; Otsubo, Shigeru; Takei, Takashi; Yumura, Wako; Kabaya, Takashi; Nihei, Hiroshi

doi:10.1093/ndt/gfh263

Cited by 106 publications

(82 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 It is currently unclear what role these molecules play within the plaques. However, recent epidemiological studies show that serum OPG levels are associated with the extent of atherosclerosis and calcification in humans 18,19 and may predict the progression of atherosclerosis and cardiovascular mortality. 20 The OPGϪ/Ϫ mouse is characterized by an osteoporotic phenotype and development of extensive medial calcification of the major blood vessels.…”

Section: Discussionmentioning

confidence: 99%

Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice

Rattazzi

Bennett

Bea

et al. 2005

ATVB

156

136

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice

Rattazzi

Bennett

Bea

et al. 2005

ATVB

156

136

View full text Add to dashboard Cite

show abstract

“…This observation indicates that OPG is an important inhibitor of calcification of blood vessel walls. Paradoxically, serum OPG levels are associated with the extent of vascular calcification in hemodialysis patients (46,51). This may be a compensatory, protective response to the progression of vascular calcification or due to the effect of OPG on decreasing bone turnover, thus impairing the ability of bone to buffer Ca load (46).…”

Section: ) (B)mentioning

confidence: 99%

Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease

Qunibi

2005

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) have a higher burden of atherosclerotic coronary artery disease compared with age-and gender-matched individuals with normal renal function. Cardiovascular calcification (CVC), a marker of atherosclerosis, is also more prevalent in these patients and is associated with serious clinical consequences. The pathogenesis of CVC is complex and includes factors that promote calcification and others that inhibit calcification. Thus, multiple therapeutic interventions should be used simultaneously to reduce the burden of calcification in patients with CKD. Thus far, interventional attempts have focused on curtailing the effects of factors that promote calcification such as management of known traditional factors for atherosclerotic coronary artery disease and on adopting specific approaches to normalize mineral metabolism, deliver adequate dialysis, and control serum cholesterol level. By contrast, interventions that may bolster the effects of inhibitors of calcification have not yet been studied well but are beginning to attract attention. Ideally, the goal of interventions is not only to slow or halt progression of calcification but also to reverse pre-existing calcification. Whether this goal is achievable is not currently known. This review examines the potential of various therapeutic interventions in reducing the CVC burden in patients with CKD. Moreover, the review is intended to stimulate more research in this area because the efficacy of these interventions has not been examined in controlled clinical trials.

show abstract

“…In adults and children with ESRD on hemodialysis, studies demonstrated a significant independent correlation between OPG levels and CAC [18,19] . Similarly, another study showed an association between OPG and ACI assessed by computed tomography scans independently of traditional and uremia-related risk factors [20] . In addition, high OPG levels have been found to correlate with faster progression of aortic calcifications during a 5-year follow-up [21] .…”

Section: Opg and Vascular Calcifications In Ckd Patientsmentioning

confidence: 83%

Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease

Spartalis

Papagianni

2016

WJN

View full text Add to dashboard Cite

Vascular calcifications are commonly observed in patients with chronic kidney disease (CKD) and contribute to the excessive cardiovascular morbidity and mortality rates observed in these patients populations. Although the pathogenetic mechanisms are not yet fully elucidated, recent evidence suggests a link between bone metabolism and the development and progression of vascular calcifications. Moreover, accumulating data indicate that receptor activator of nuclear factor κB ligand/osteoprotegerin axis which plays essential roles in the regulation of bone metabolism is also involved in extra-osseous bone formation. Further studies are required to establish the prognostic significance of the above biomarkers as predictors of the presence and severity of vascular calcifications in CKD patients and of cardiovascular morbidity and mortality. Moreover, randomized clinical trials are needed to clarify whether inhibition of osteoclast activity will protect from vascular calcifications. Core tip: Vascular calcifications are commonly observed in chronic kidney disease patients and recently mounting evidence suggest that Receptor activator of nuclear factor κB ligand/osteoprotegerin axis controls both bone metabolism and extra-osseous bone formation. Further studies are required to establish the role of these biomarkers as predictors of the presence and severity of vascular calcifications and of cardiovascular morbidity and mortality. Moreover, randomized clinical trials are needed to clarify whether inhibition of osteoclast activity will protect from vascular calcifications.Spartalis M, Papagianni A. Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients EDITORIAL 1 January 6, 2016|Volume 5|Issue 1|

show abstract

Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients

Abstract: These findings show that serum OPG levels are associated with the extent of vascular calcification, suggesting that OPG may be involved in the development of vascular calcification in haemodialysis patients.

Cited by 106 publications

References 11 publications

Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice

Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice

Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease

Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease

Contact Info

Product

Resources

About